BETA CELL TECHNOLOGIES
dELIVERING A NEW FRONTIER IN CELL THERAPY
Our
Inspiration
At Beta Cell Technologies, we are focused on a critical global challenge: more than 8.7 million people live with Type 1 Diabetes, alongside millions more affected by endocrine disorders, facing a lifelong cycle of management and risk. While science has made remarkable progress—enabling the creation of healthy, hormone-producing cells from stem cells—the ability to safely deliver and protect these cells without harsh, lifelong immune suppression remains unsolved. We exist to bridge this gap, advancing cell therapy solutions that could transform what’s possible into what’s accessible—and move us closer to a functional cure.
Our
Technology
Beta Cell Technologies is advancing cellular therapy through its innovative Intracutaneous Cell Delivery Vehicle (ICDV)—a specialised platform designed to provide a safe, protective, and high-functioning environment for transplanted cells. Built to bridge the gap between laboratory breakthroughs and real-world patient outcomes, the ICDV is initially focused on Type 1 Diabetes but engineered to support a broader range of endocrine applications, including pancreatic islets and adrenal cells. At its core is the world-renowned NovoSorb BTM platform, pioneered by Prof John Greenwood AM, now reimagined by Prof Greenwood and Prof Toby Coates AO to create a highly vascularised environment optimised for endocrine cell delivery.
Latest
News
Medical dream team working to find a cure for diabetes
From the horror of the 2002 Bali bombings a story has emerged of friendship, ingenuity and innovation, with the near death of a footballer leading to a medical breakthrough that is revolutionising patient care. It involves four men from very different backgrounds who have now become mates, and whose extraordinary and accidental collaboration is giving hope to diabetes sufferers worldwide – even promising a potential cure for Type 1 diabetes.
NovoSorb BTM delivers positive First in Man results in Cell Therapies
PolyNovo is pleased to announce that Professor Toby Coates AO, Director of Beta Cell
Technologies Pty Ltd (Beta Cell) presented to the Joint Congress of ESPE and ESE on 12 May in
Copenhagen outlining the results of PolyNovo’s NovoSorb’s leading role in treating and managing
Type 1 diabetes (T1D).
Beta Cell Technologies Announces Human Data Trial Results
Professor Toby Coates presented the 12 month results of Beta Cell’s First in Human INCEPTR study at the Congress of the European Society of Paediatric Endocrinology and European Society of Endocrinology (ESPE and ESE ) meeting in Copenhagen, Denmark.
our Partners
